-
Je něco špatně v tomto záznamu ?
6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents
P. Naus, R. Pohl, I. Votruba, P. Dzubak, M .Hajduch, R. Ameral, G. Birkus, T. Wang, A.S. Ray, R. Mackman, T. Cihlar, M. Hocek
Jazyk angličtina Země Spojené státy americké
Typ dokumentu práce podpořená grantem
- MeSH
- buněčný cyklus účinky léků MeSH
- cytostatické látky farmakologie chemická syntéza chemie MeSH
- lidé MeSH
- molekulární struktura MeSH
- nádorové buněčné linie MeSH
- proliferace buněk účinky léků MeSH
- protinádorové látky farmakologie chemická syntéza chemie MeSH
- puriny farmakologie chemická syntéza chemie MeSH
- ribonukleosidy farmakologie chemická syntéza chemie MeSH
- screeningové testy protinádorových léčiv MeSH
- stereoizomerie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
A series of novel 7-deazapurine ribonucleosides bearing an alkyl, aryl, or hetaryl group in position 6 and H, F, or Cl atom in position 7 has been prepared either by Pd-catalyzed cross-coupling reactions of the corresponding protected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with alkyl- or (het)arylorganometallics followed by deprotection, or by single-step aqueous phase cross-coupling reactions of unprotected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with (het)arylboronic acids. Significant cytostatic effect was detected with a substantial proportion of the prepared compounds. The most potent were 7-H or 7-F derivatives of 6-furyl- or 6-thienyl-7-deazapurines displaying cytostatic activity in multiple cancer cell lines with a geometric mean of 50% growth inhibition concentration ranging from 16 to 96 nM, a potency comparable to or better than that of the nucleoside analogue clofarabine. Intracellular phosphorylation to mono- and triphosphates and the inhibition of total RNA synthesis was demonstrated in preliminary study of metabolism and mechanism of action studies.
- 000
- 03379naa a2200589 a 4500
- 001
- bmc12008668
- 003
- CZ-PrNML
- 005
- 20130520134250.0
- 008
- 120316s2010 xxu eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Nauš, Petr, $d 1974- $7 xx0124746 $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences & IOCB Research Center, Flemingovo nam. 2, CZ-16610 Prague 6, Czech Republic.
- 245 10
- $a 6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents / $c P. Naus, R. Pohl, I. Votruba, P. Dzubak, M .Hajduch, R. Ameral, G. Birkus, T. Wang, A.S. Ray, R. Mackman, T. Cihlar, M. Hocek
- 520 9_
- $a A series of novel 7-deazapurine ribonucleosides bearing an alkyl, aryl, or hetaryl group in position 6 and H, F, or Cl atom in position 7 has been prepared either by Pd-catalyzed cross-coupling reactions of the corresponding protected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with alkyl- or (het)arylorganometallics followed by deprotection, or by single-step aqueous phase cross-coupling reactions of unprotected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with (het)arylboronic acids. Significant cytostatic effect was detected with a substantial proportion of the prepared compounds. The most potent were 7-H or 7-F derivatives of 6-furyl- or 6-thienyl-7-deazapurines displaying cytostatic activity in multiple cancer cell lines with a geometric mean of 50% growth inhibition concentration ranging from 16 to 96 nM, a potency comparable to or better than that of the nucleoside analogue clofarabine. Intracellular phosphorylation to mono- and triphosphates and the inhibition of total RNA synthesis was demonstrated in preliminary study of metabolism and mechanism of action studies.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a protinádorové látky $x farmakologie $x chemická syntéza $x chemie $7 D000970
- 650 02
- $a buněčný cyklus $x účinky léků $7 D002453
- 650 02
- $a nádorové buněčné linie $7 D045744
- 650 02
- $a proliferace buněk $x účinky léků $7 D049109
- 650 02
- $a cytostatické látky $x farmakologie $x chemická syntéza $x chemie $7 D054697
- 650 02
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 02
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 02
- $a lidé $7 D006801
- 650 02
- $a molekulární struktura $7 D015394
- 650 02
- $a puriny $x farmakologie $x chemická syntéza $x chemie $7 D011687
- 650 02
- $a ribonukleosidy $x farmakologie $x chemická syntéza $x chemie $7 D012263
- 650 02
- $a stereoizomerie $7 D013237
- 650 02
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pohl R
- 700 1_
- $a Votruba I
- 700 1_
- $a Džubák, Petr $7 xx0080445
- 700 1_
- $a Hajdúch, Marián, $d 1969- $7 xx0050218
- 700 1_
- $a Ameral R $7 gn_A_00005530
- 700 1_
- $a Birkus G
- 700 1_
- $a Wang T
- 700 1_
- $a Ray AS
- 700 1_
- $a Mackman R
- 700 1_
- $a Cihlar T
- 700 1_
- $a Hocek M
- 773 0_
- $t Journal of Medicinal Chemistry $p J Med Chem $g Roč. 53, č. 1 (2010), s. 460-470 $w MED00010049 $x 0020-8868
- 773 0_
- $p J Med Chem $g 53(1):460-70, 2010 Jan 14
- 910 __
- $a ABA008 $b x $y 4
- 990 __
- $a 20120319124615 $b ABA008
- 991 __
- $a 20130520134610 $b ABA008
- 999 __
- $a ok $b bmc $g 902010 $s 765564
- BAS __
- $a 3
- BMC __
- $a 2010 $b 53 $c 1 $d 460-470 $m Journal of medicinal chemistry $x MED00010049
- LZP __
- $a 2012-1Q10/